NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will participate in the following conferences:

  • The Sachs 10th Annual Biotech in Europe Investor Forum, September 29 - 30, 2010 at the Radisson Blu Hotel in Zurich, Switzerland. Dr. Bloch will be part of the CNS & Neurology panel session on Wednesday, September 29th at 5:30 pm (local time) and will present a corporate overview on Thursday, September 30th at 11:45 am (local time).
  • The BIO Investor Forum, October 5 - 6, 2010 at the Palace Hotel in San Francisco. Dr. Bloch will present a corporate overview on Tuesday, October 5th at 2:30 pm (local time).

These presentations will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.

About NeurAxon, Inc.

NeurAxon, Inc. ( discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.


MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science  General Health



Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.